Signal from the log
Soufflé Therapeutics
135 M$ · Series B · United States · Biotech
Soufflé Therapeutics développe des médicaments à ARN interférent guidés vers des cellules précises hors du foie, grâce à sa plateforme REMEDY. La série B, menée par Juvia Group, doit faire entrer en essais ses programmes dans la dystrophie FSHD, l'insuffisance cardiaque et un trouble musculaire et métabolique.
Article
Announced on , logged by the watch of 13 October 2026.
- Operation
- Funding round
- Announced amount
- 135 M$
- Stage
- Series B
- Country
- United States
- Sector
- Biotech
What the log says
Editorial note, in French
Sujet traité. L'article donne les sources et la position de Bolus.
The investors
Led by Juvia Group , with TCG Crossover Management , BB Biotech , Fidelity Management & Research Company , Balyasny Asset Management
Provenance
Source businesswire,endpoints
Logged on 13 October 2026
Description Written in French during the watch run. Written during the watch run, after reading the issuer's press release or the source article.
Verification Amounts and fund names were double checked against the issuer's press release or an official filing.
What this status means
Article The operation led to an article, with its sources checked one by one.
The rule A signal is never removed from the log. A round set aside stays readable with its reason, because a collection you cannot reread is a collection you cannot correct.